Cardiol Therapeutics (TSE:CRDL) Stock Price Up 10.5% – Time to Buy?

Cardiol Therapeutics Inc. (TSE:CRDL) shares traded up 10.5% on Friday . The stock traded as high as C$1.74 and last traded at C$1.69. 277,314 shares changed hands during mid-day trading, an increase of 199% from the average session volume of 92,647 shares. The stock had previously closed at C$1.53.

Cardiol Therapeutics Stock Performance

The company’s fifty day simple moving average is C$1.40 and its two-hundred day simple moving average is C$1.44. The company has a debt-to-equity ratio of 1.40, a quick ratio of 6.84 and a current ratio of 3.89. The stock has a market capitalization of C$192.09 million, a P/E ratio of -4.20 and a beta of 0.94.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.